Exelixis (NASDAQ: EXEL)
Exelixis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Exelixis Company Info
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
News & Analysis
Exelixis Q2 Revenue Falls 11 Percent
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Why Exelixis Stock Is Skyrocketing Today
Investing in Biotech Stocks in 2025
Why Exelixis Stock Trounced the Market on Thursday
Exelixis Posts 63.7% Profit Surge
Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.
Exelixis' Sales, Earnings Surge in Q3
The cancer drug specialist's robust results were driven by its cabozantinib franchise.
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy.
Valuation
Earnings Transcripts
Exelixis EXEL Q2 2025 Earnings Call Transcript
None
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2024.
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2024.
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.